Literature DB >> 11699393

Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation.

K Ohyashiki1, H Iwama, N Yahata, T Tauchi, K Kawakubo, T Shimamoto, J H Ohyashiki.   

Abstract

Myelodysplastic syndromes (MDS) are characterized by cytopenias in the blood and dysplastic features in the hematopoietic cells. Although the impact of cytogenetic abnormalities is considerable for prognosis, the exact genetic mechanism of MDS remains undetermined. In this study we assessed cytogenetic changes, microsatellite alterations, and telomere dynamics in order to obtain further insight into the pathogenesis of MDS. Thirty-three percentage of MDS patients and 60% of post-MDS acute leukemia (post-MDS AML) had de novo microsatellite changes. In the MDS phase, however, > 60% of patients showed reduction of telomere lengths without microsatellite changes, indicating that telomere reduction in most MDS patients does not seem to be directly linked to genome instability, or that reduction of telomere length does not induce microsatellite changes in the MDS phase. Some MDS patients had microsatellite changes without telomerase elevation, indicating that genome instability might accumulate during the disease progression in some MDS patients, and this condition (cellular senescence) may be related to ineffective hemopoiesis in MDS patients. In contrast, 40% of post-MDS AML patients had elevated telomerase activity with microsatellite changes, indicating that approximately 40% of patients with post-MDS AML patients had accumulation of genome instability resulting in elevated telomerase activity in an attempt to obtain genetic stability. However, the remaining MDS patients had microsatellite changes without telomerase up-regulation, suggesting that some MDS had genome instability even after leukemic transformation. Most MDS patients with elevated telomerase activity in the AML phase had elevated telomerase activity even in the MDS phase without apparent change in telomere length before and after leukemic transformation. These findings indicate that telomerase activity in the MDS phase may be independent of telomere length, although telomere shortening seems to be related to genomic instability, and this process may be linked to apoptosis of MDS cells.

Entities:  

Mesh:

Year:  2001        PMID: 11699393     DOI: 10.3109/10428190109064585

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

2.  Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

Authors:  A Mario Marcondes; Aravind Ramakrishnan; H Joachim Deeg
Journal:  Curr Cancer Ther Rev       Date:  2009-11-01

3.  No telomere shortening in marrow stroma from patients with MDS.

Authors:  A Mario Marcondes; Steven Bair; Peter S Rabinovitch; Ted Gooley; H Joachim Deeg; Rosana Risques
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

4.  Telomerase reverse transcriptase (TERT) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML).

Authors:  Salah Aref; Mohamed Sabry El-Ghonemy; Tarek Elsayed Abouzeid; Amr Mohamed El-Sabbagh; Mohamed Ali El-Baiomy
Journal:  Med Oncol       Date:  2014-08-10       Impact factor: 3.064

5.  Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.

Authors:  Sujata Chakraborty; Can-Lan Sun; Liton Francisco; Melanie Sabado; Liang Li; Karen L Chang; Stephen Forman; Smita Bhatia; Ravi Bhatia
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

6.  Cigarette Smoking and the Risk of Adult Myeloid Disease: A Meta-Analysis.

Authors:  Peng Wang; Huifang Liu; Ting Jiang; Julun Yang
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

7.  Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.

Authors:  Hee Sue Park; Jungeun Choi; Cha Ja See; Jung Ah Kim; Si Nae Park; Kyongok Im; Sung Min Kim; Dong Soon Lee; Sang Mee Hwang
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

8.  Short telomere length and its correlation with gene mutations in myelodysplastic syndrome.

Authors:  Sang Mee Hwang; Seon Young Kim; Jung Ah Kim; Hee-Sue Park; Si Nae Park; Kyongok Im; Kwantae Kim; Sung-Min Kim; Dong Soon Lee
Journal:  J Hematol Oncol       Date:  2016-07-28       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.